Radiopharm Theranostics Limited (RADX)

Every figure this model derived for RADX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2023-06-30
cash 29,116,835 CashAndCashEquivalents 2025-06-30
current assets 39,853,988 CurrentAssets 2025-06-30
current liabilities 14,932,985 CurrentLiabilities 2025-06-30
equity 42,871,904 Equity 2025-06-30
interest expense 65,300 FinanceCosts 2025-06-30
ocf -36,645,477 CashFlowsFromUsedInOperatingActivities 2025-06-30
revenue 3,633,422 RevenueFromContractsWithCustomers 2025-06-30
sbc 1,895,348 AdjustmentsForSharebasedPayments 2025-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RADX on one particular measure came for.

RatioValue
cash operating margin-927.03
current ratio2.67
current ratio reported2.67
dilution pct439.11
fcf margin-1008.57
interest cover-584.59
operating margin-1050.63
owner earnings margin-1060.73
revenue growth1114.27
revenue growth per share125.23
roic-219.25
rule of 4063.63
sbc pct revenue52.16

What to be careful about

What this model itself distrusts about RADX's figures. Written by the derivation as it ran, not added afterwards.